De Rosa FG - Search Results

1

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.

Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Di Perri G. Boglione L, et al. Among authors: de rosa fg. Liver Int. 2013 Apr;33(4):580-5. doi: 10.1111/liv.12091. Epub 2013 Jan 14. Liver Int. 2013. PMID: 23311449

2

Healthy ranges for alanine aminotransferase levels.

De Rosa FG, Bonora S, Di Perri G. De Rosa FG, et al. Ann Intern Med. 2003 Jan 21;138(2):156-7; author reply 156-7. doi: 10.7326/0003-4819-138-2-200301210-00021. Ann Intern Med. 2003. PMID: 12529101 No abstract available.

3

Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.

De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R, Di Perri G. De Rosa FG, et al. J Antimicrob Chemother. 2006 Feb;57(2):360-3. doi: 10.1093/jac/dki458. Epub 2006 Jan 5. J Antimicrob Chemother. 2006. PMID: 16396921

4

Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient.

De Rosa FG, Audagnotto S, Bargiacchi O, Garazzino S, Aguilar Marucco D, Veronese L, Canta F, Bonora S, Sinicco A, Di Perri G. De Rosa FG, et al. J Infect. 2006 Nov;53(5):e215-8. doi: 10.1016/j.jinf.2006.01.023. Epub 2006 Mar 20. J Infect. 2006. PMID: 16549201

5

The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b.

De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, Raiteri R, Calleri G, Di Perri G. De Rosa FG, et al. Antivir Ther. 2006;11(2):165-71. Antivir Ther. 2006. PMID: 16640097

6

Acute hepatitis C: dosage and compliance.

De Rosa F, Cariti G, Di Perri G. De Rosa F, et al. Hepatology. 2006 Aug;44(2):511; author reply 511-2. doi: 10.1002/hep.21273. Hepatology. 2006. PMID: 16871564 No abstract available.

7

Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users.

De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G, Lesioba O, Belloro S, Raiteri R, Di Perri G. De Rosa FG, et al. Clin Infect Dis. 2007 Sep 1;45(5):583-8. doi: 10.1086/520660. Epub 2007 Jul 19. Clin Infect Dis. 2007. PMID: 17682992 Clinical Trial.

8

SPIR01 and SPIR02: a two-year 1-day point prevalence multicenter study of infections in intensive care units in Piedmont, Italy.

De Rosa FG, Garazzino S, Audagnotto S, Bargiacchi O, Zeme DA, Gramoni A, Barberis B, Ranieri VM, Di Perri G; Piedmont Intensive Care Unit Network. De Rosa FG, et al. New Microbiol. 2008 Jan;31(1):81-7. New Microbiol. 2008. PMID: 18437845 Free article.

9

Prevention and diagnosis of ventilator-associated pneumonia: a regional survey in Italy.

De Rosa FG, Michelazzo M, Pagani N, Di Perri G, Ranieri VM, Barberis B. De Rosa FG, et al. Chest. 2009 Mar;135(3):881-882. doi: 10.1378/chest.08-2763. Chest. 2009. PMID: 19265103 No abstract available.

10

Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients.

De Rosa FG, Mollaretti O, Audagnotto S, De Blasi T, Cariti G, Marucco DM, Bonora S, Perri GD. De Rosa FG, et al. Among authors: de blasi t. Clin Infect Dis. 2009 Jun 1;48(11):1636-7. doi: 10.1086/598995. Clin Infect Dis. 2009. PMID: 19416030 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters